NCT01538238View on ClinicalTrials.gov

pazopanib_NCRCC,Ph2 STUDY

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 2, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

November 14, 2015

Conditions
Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
Interventions
DRUG

pazopanib

pazopanib 800mg qd until progression or unacceptable toxicity

Trial Locations (1)

Unknown

Samsung medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT01538238 - pazopanib_NCRCC,Ph2 STUDY | Biotech Hunter | Biotech Hunter